Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 3/20 | 0.37 |
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8509889 | 1.00 | TSHR (0.46) | TSHRABCC4MAPTALDH1A1TRPA1 | |
| SCHEMBL2566885 | 1.00 | — | — | |
| SCHEMBL2535243 | 1.00 | TSHR (0.46) | TSHRABCC4MAPTALDH1A1TRPA1 | |
| SCHEMBL937633 | 0.97 | — | — | |
| SCHEMBL232494 | 0.89 | — | — | |
| SCHEMBL15272648 | 0.78 | TSHR (0.50) | TSHRABCC4MAPTALDH1A1TRPA1 | |
| SCHEMBL7525 | 0.77 | — | — | |
| SCHEMBL18187344 | 0.76 | TSHR (0.69) | TSHRABCC4MAPTALDH1A1TRPA1 | |
| SCHEMBL18187333 | 0.76 | TSHR (0.69) | TSHRABCC4MAPTALDH1A1TRPA1 | |
| SCHEMBL2850911 | 0.76 | TSHR (0.69) | TSHRABCC4MAPTALDH1A1TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113683837-A | Impact-resistant co-polypropylene and preparation method thereof | 中国石油天然气股份有限公司 | 2021-11-23 | — | — | CN | disclosed |
| EP-1691845-A4 | COMPOUNDS CONTAINING MATRIX METALLOPROTEINASE SUBSTRATES AND METHODS OF THEIR USE | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2009-02-25 | — | — | EP | disclosed |
| EP-1691845-A1 | COMPOUNDS CONTAINING MATRIX METALLOPROTEINASE SUBSTRATES AND METHODS OF THEIR USE | Bristol-Myers Squibb Pharma Company (US) | 2006-08-23 | — | — | EP | disclosed |
| US-20050106100-A1 | Compounds containing matrix metalloproteinase substrates and methods of their use | LANTHEUS MEDICAL IMAGING, INC. | 2005-05-19 | — | — | US | disclosed |
| WO-2005023314-A1 | COMPOUNDS CONTAINING MATRIX METALLOPROTEINASE SUBSTRATES AND METHODS OF THEIR USE | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050106100-A1 | Compounds containing matrix metalloproteinase substrates and methods of their use | MMP1, MMP10, MMP8 | TSHR 4185/4885ABCC4 4088/4885MAPT 2533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.